{
    "clinical_study": {
        "@rank": "41721", 
        "arm_group": {
            "arm_group_label": "Molecular Breast Imaging", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this research is to evaluate whether repeating a screening Molecular Breast\n      Imaging (MBI) study two years after an initial screening MBI study further improves breast\n      cancer detection in women with dense breast tissue."
        }, 
        "brief_title": "Low-dose Molecular Breast Imaging: Comparison of Breast Cancer Detection Rate at Initial Screening and Two-year Follow-up", 
        "condition": "Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        1)Past prior screening mammogram within the previous 11-24 months interpreted as\n        heterogeneously dense or extremely dense and negative or benign [Breast Imaging Reporting\n        and Data System (BI-RADS) Category 1 or 2]\n\n        Exclusion Criteria:\n\n        Subjects will be excluded if they:\n\n          1. Are unable to understand and sign the consent form\n\n          2. Are pregnant or lactating\n\n          3. Are physically unable to sit upright and still for 40 minutes\n\n          4. Have self-reported signs or symptoms that may suggest breast cancer (palpable mass,\n             bloody nipple discharge, axillary mass, etc.)\n\n          5. Have had needle biopsy within 3 months, or breast surgery or radiation within 1 year\n             prior to the study\n\n          6. Are currently receiving chemotherapy or tamoxifen, raloxifene, or an aromatase\n             inhibitor for adjuvant therapy or chemoprevention\n\n          7. Have undergone bilateral mastectomy\n\n          8. Have had a prior MBI within 20 months of scheduled study MBI."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "80 Years", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "2000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 24, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01723124", 
            "org_study_id": "12-004322"
        }, 
        "intervention": {
            "arm_group_label": "Molecular Breast Imaging", 
            "description": "Molecular Breast Imaging (MBI) utilizes small high resolution gamma camera detectors in a dual-detector configuration to image the breast following the administration of a radiopharmaceutical that accumulates preferentially in breast tumors.", 
            "intervention_name": "Molecular Breast Imaging", 
            "intervention_type": "Procedure"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Dense breast tissue", 
            "breast cancer screening", 
            "molecular breast imaging", 
            "breast cancer", 
            "breast"
        ], 
        "lastchanged_date": "November 7, 2013", 
        "link": [
            {
                "description": "Mayo Clinic News", 
                "url": "http://newsblog.mayoclinic.org/2008/09/03/breast-cancer-molecular-breast-imaging-mammography/"
            }, 
            {
                "description": "Mayo Clinic You Tube Channel", 
                "url": "http://www.youtube.com/watch?v=DOQBLe8MdH0"
            }
        ], 
        "location": {
            "facility": {
                "address": {
                    "city": "Rochester", 
                    "country": "United States", 
                    "state": "Minnesota", 
                    "zip": "55905"
                }, 
                "name": "Mayo Clinic in Rochester"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Comparison of Breast Cancer Detection Rate for Prevalent Screen Low-dose Molecular Breast Imaging and Incident Biennial Screen Low-dose Molecular Breast Imaging in Women With Mammographically Dense Breasts", 
        "other_outcome": {
            "description": "The breast cancer detection rate for Year 0 and Year 2 MBI will be compared to each other and to the breast cancer detection rates for the screening mammograms performed in Year 0 and Year 2.", 
            "measure": "Comparison of breast cancer detection rate for Year 0 and Year 2.", 
            "safety_issue": "No", 
            "time_frame": "Year 2 of study"
        }, 
        "overall_official": {
            "affiliation": "Mayo Clinic", 
            "last_name": "Deborah Rhodes, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Suspended", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "July 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The Year 0 MBI will be interpreted in isolation, with the radiologist blinded to Year 0 mammogram results and all relevant clinical information.", 
            "measure": "\u2022 Molecular Breast Imaging (MBI) scan", 
            "safety_issue": "No", 
            "time_frame": "Performed at Year 0 of study"
        }, 
        "reference": {
            "PMID": "21045179", 
            "citation": "Rhodes DJ, Hruska CB, Phillips SW, Whaley DH, O'Connor MK. Dedicated dual-head gamma imaging for breast cancer screening in women with mammographically dense breasts. Radiology. 2011 Jan;258(1):106-18. Epub 2010 Nov 2."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01723124"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Mayo Clinic", 
            "investigator_full_name": "Deborah Rhodes", 
            "investigator_title": "MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "The Year 2 MBI will be interpreted in comparison with the Year 0 MBI but in isolation from the Year 2 mammogram.", 
            "measure": "Molecular Breast Imaging (MBI) scan", 
            "safety_issue": "No", 
            "time_frame": "Performed at Year 2 of study"
        }, 
        "source": "Mayo Clinic", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Mayo Clinic", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "November 2013", 
        "why_stopped": "Evaluating the quality of images from lower dose of 99m Sestamibi (4mCi)."
    }
}